Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000926617-17-000068
Filing Date
2017-11-08
Accepted
2017-11-08 16:13:50
Documents
34
Period of Report
2017-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q vrml-20170930x10q.htm 10-Q 985165
2 EX-31.1 vrml-20170930xex31_1.htm EX-31.1 15024
3 EX-31.2 vrml-20170930xex31_2.htm EX-31.2 15272
4 EX-32.1 vrml-20170930xex32_1.htm EX-32.1 11628
5 GRAPHIC vrml-20170930x10qg001.jpg GRAPHIC 18865
  Complete submission text file 0000926617-17-000068.txt   2631586

Data Files

Seq Description Document Type Size
6 EX-101.INS vrml-20170930.xml EX-101.INS 339011
7 EX-101.SCH vrml-20170930.xsd EX-101.SCH 20726
8 EX-101.CAL vrml-20170930_cal.xml EX-101.CAL 30396
9 EX-101.DEF vrml-20170930_def.xml EX-101.DEF 62132
10 EX-101.LAB vrml-20170930_lab.xml EX-101.LAB 179637
11 EX-101.PRE vrml-20170930_pre.xml EX-101.PRE 140469
Mailing Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738
Business Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738 512-519-0400
VERMILLION, INC. (Filer) CIK: 0000926617 (see all company filings)

EIN.: 330595156 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34810 | Film No.: 171186765
SIC: 2835 In Vitro & In Vivo Diagnostic Substances